Table 1.
Study | N | Study type | Inclusion | Median dose | Child-Pugh Score | Outcome | Toxicity (≥ Gr 2) | Comments |
---|---|---|---|---|---|---|---|---|
Chiba et al. (2005) | 162 | Retrospective | Local HCC, <3 lesions. | 72 CGE (50–88) 4.5 CGE/fx (2.9–6) |
A: 50.6% B: 38.3% C: 6.2% |
5 yr OS: 23.5% 5 yr LC: 86.9% Class A and solitary lesion: 5 yr OS 53.5% |
Acute: 16.6% Late: 2.7% |
HCV in 80%; Prior and concurrent treatment NS. |
Nakayama et al. (2009) | 318 | Retrospective | Local HCC, <3 lesions, PS 0-2. | 72.6 CGE (55/10fx-79.2/22fx) | A: 73.6% B: 24.2% C: 2.2% |
5 yr OS: 44.6% 5 yr LC: NS |
Acute:12.2% Late: 4% |
HCV in 78%; Dose altered based upon tumor location; 56.6% treated with other local modality prior to proton. |
Bush et al. (2004) | 34 | Prospective | Local HCC, Child score ≤ 10. | 63 CGE/15 fx | Score: 5–6: 14 7–8: 7 (?) 9–10: 7 (?) |
2 yr OS: 55% 2 yr LC: 75% |
Acute (not graded): 60%, no hospitalizations Late: Post-treatment ascites in 17% |
HCV NS; 6 patients received liver transplant post-treatment with 2 CR. |
Kawashima et al. (2005) | 30 | Prospective | Local HCC, ≥ 20 years old, all tumors within target volume and not invasive of GI tract, no previous abdominal radiation, no recent HCC treatment, bilirubin ≤ 3.0 mg/dL, AST and ALT < 5.0 X ULN, PS 0-2. | 76 CGE/20 fx | A: 67% B: 33% |
3 yr OS: 62% 3 yr LC: ~95% |
Acute: NS Late: HI within 6 months of treatment in 27% |
HCV in 90%; ICG R15 used to determine functional liver reserve. |
Fukumitsu et al. (2009) | 51 | Prospective | Local HCC , ≤3 tumors ≤10 cm in diameter and ≥2 cm from the porta hepatis or GI tract, PS 0-2. | 66 CGE /10 fx | A: 80.4% B: 19.6% |
5 yr OS: 38.7% 5 yr LC: 87.8%; CR in 57% |
Acute: NS Late: 8% |
HCV in 66.6%; 65% had prior local therapy. |
Abbreviations: HCC – Hepatocellular carcinoma, PS –performance status, Fx – fraction, OS – overall survival, LC – local control, NS – not specified, CR – complete response, HCV – hepatitis C virus & ICG R15 - indocyanine green clearance and retention rate at 15 minutes, HI – hepatic insufficiency.